Cambridge Healthtech Institute’s 7th Annual

Adoptive Cell Therapy

Engineering the Second Generation of CAR Ts, TCRs, and TILs

August 11-12, 2020



Efforts to engineer CAR Ts, NKs, TCRs, and TILs with greater precision, safety profiles, and efficacy are leading to the second generation of improved adoptive cell therapies. With multiple engineered receptors already making preclinical impact, many biotech and pharma companies are preparing for the next wave of clinical trials. The end goal is still the same: improved patient outcomes. However, there remain technical considerations and translational challenges relating to cell therapy development, manufacturing practicability, clinical trial approaches, cell quality and persistence, and patient management. Cambridge Healthtech Institute’s Seventh Annual Adoptive Cell Therapy conference focuses on the next steps needed to deliver CAR Ts, TCRs, and TILs into the clinic.

Preliminary Agenda

TARGETING SOLID TUMORS

Identification of Immunogenic Targets in Solid Tumors

Hanspeter Gerber, PhD, Senior Vice President & CSO, 3T Biosciences

Personalized NeoTCR-T Cell Therapies for Solid Tumors

Roel Funke, PhD, Senior Director, Clinical Science, PACT Pharma

Development of TAC-T Cells for Treatment of Solid Tumors

Andreas Bader, PhD, Senior Vice President, R&D, Triumvira

Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy

Michael Klichinsky, PharmD, PhD, Co-founder & Vice President, Discovery, Carisma Therapeutics

Targeting Tumor-Reactive T Cells for Adoptive Immunotherapy in Humans

Andrew Weinberg, PhD, Chief, Laboratory of Basic Immunology, Providence Health & Services; CSO, AgonOx

TruC-T Cells: Redefining T Cell Therapies for Cancer

Garry Menzel, PhD, President & CEO, TCR2 Therapeutics

 

OFF-THE-SHELF, Allogeneic CELL THERAPY

Speakers to be Announced

GENETIC ENGINEERING FOR CELL THERAPY

Talk Title to be Announced

Christina Coughlin, MD, PhD, CMO, Rubius Therapeutics

 

GAMMA DELTA T CELLS

Getting to Zero: Drug-Resistant Immunotherapy as Adjunctive Therapy in Minimal Residual Primary Cancers

Lawrence Lamb, PhD, Executive Vice President & CSO, Incysus

Bispecific Gamma-Delta T Cell Engager Platform

Rob Roovers, PhD, Senior Director, Preclinical Development, Lava Therapeutics


EMERGING CONSTRUCTS AND COMBINATIONS

Talk Title to be Announced

David Fontana, PhD, Vice President, Cell Therapy Franchise, Juno Therapeutics, a Bristol-Myers Squibb Company

Talk Title to be Announced

Thomas Lars Andresen, PhD, CSO & Co-Founder, Torque Therapeutics

PLENARY KEYNOTE SESSION

PD-1 Antibodies Either as Monotherapy or Precision Medicine Informed Combinations are Transforming Cancer Care

Roy Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories




For more details on the conference, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com


Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com